Comparative Pharmacology
Head-to-head clinical analysis: H R 50 versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: H R 50 versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
H.R.-50 vs TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
12.5 mg orally twice daily
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Category C
Category D/X
Androgen
Androgen